Stefan Faderl

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Concepts & Ideas

Chemicals & Drugs

Disorders

Procedures

Anatomy

Philadelphia Chromosome

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Ravandi Farhad; Aribi Ahmed; O'Brien Susan; Faderl Stefan; Jones Dan; Ferrajoli Alessandra; Huang Xuelin; York Sergernne; Pierce Sherry; Wierda William; Kontoyiannis Dimitrios; Verstovsek Srdan; Pro Barbara; Fayad Luis; Keating Michael; Kantarjian Hagop
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
Kantarjian Hagop; O'Brien Susan; Ravandi Farhad; Borthakur Gautam; Faderl Stefan; Bueso-Ramos Carlos; Abruzzo Lynne; Pierce Sherry; Shan Jianqin; Issa Jean-Pierre; Garcia-Manero Guillermo
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
Quintás-Cardama Alfonso; De Souza Santos Fabio Pires; Kantarjian Hagop; O'Brien Susan; Faderl Stefan; Awais Ahmed; Borthakur Gautam; Cortes Jorge
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Stefan Faderl (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Ravandi Farhad; Aribi Ahmed; O'Brien Susan; Faderl Stefan; Jones Dan; Ferrajoli Alessandra; Huang Xuelin; York Sergernne; Pierce Sherry; Wierda William; Kontoyiannis Dimitrios; Verstovsek Srdan; Pro Barbara; Fayad Luis; Keating Michael; Kantarjian Hagop
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(32):5425-30.
2009: Kantarjian Hagop; O'Brien Susan; Ravandi Farhad; Borthakur Gautam; Faderl Stefan; Bueso-Ramos Carlos; Abruzzo Lynne; Pierce Sherry; Shan Jianqin; Issa Jean-Pierre; Garcia-Manero Guillermo
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
Cancer 2009;115(22):5202-9.
2009: Quintás-Cardama Alfonso; De Souza Santos Fabio Pires; Kantarjian Hagop; O'Brien Susan; Faderl Stefan; Awais Ahmed; Borthakur Gautam; Cortes Jorge
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.
Cancer 2009;115(17):3935-43.
2009: Alvarado Yesid; Kantarjian Hagop; O'Brien Susan; Faderl Stefan; Borthakur Gautam; Burger Jan; Wierda William; Garcia-Manero Guillermo; Shan Jianqin; Cortes Jorge
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
Cancer 2009;115(16):3709-18.
2009: Borthakur Gautam; Lin E; Jain Nitin; Estey Elihu E; Cortes Jorge E; O'Brien Susan; Faderl Stefan; Ravandi Farhad; Pierce Sherry; Kantarjian Hagop
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
Cancer 2009;115(14):3217-21.
2009: Garg R; Faderl S; Garcia-Manero G; Cortes J; Koller C; Huang X; York S; Pierce S; Brandt M; Beran M; Borthakur G; Kantarjian H; Ravandi F
Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(7):1297-302.
2009: De Padua Silva L; de Lima M; Kantarjian H; Faderl S; Kebriaei P; Giralt S; Davisson J; Garcia-Manero G; Champlin R; Issa J-P; Ravandi F
Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome.
Bone marrow transplantation 2009;43(11):839-43.
2009: Thomas Deborah A; O'Brien Susan; Jorgensen Jeffrey L; Cortes Jorge; Faderl Stefan; Garcia-Manero Guillermo; Verstovsek Srdan; Koller Charles; Pierce Sherry; Huh Yang; Wierda William; Keating Michael J; Kantarjian Hagop M
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
Blood 2009;113(25):6330-7.
2009: Faderl Stefan; Pal Ashutosh; Bornmann William; Albitar Maher; Maxwell David; Van Quin; Peng Zhenghong; Harris David; Liu Zhiming; Hazan-Halevy Inbal; Kantarjian Hagop M; Estrov Zeev
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
Cancer research 2009;69(9):3910-7.
2009: Vega-Ruiz Arturo; Faderl Stefan; Estrov Zeev; Pierce Sherry; Cortes Jorge; Kantarjian Hagop; Ravandi Farhad
Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience.
International journal of hematology 2009;89(4):489-96.
2009: Garg Ravin; Kantarjian Hagop; Thomas Deborah; Faderl Stefan; Ravandi Farhad; Lovshe Denise; Pierce Sherry; O'Brien Susan
Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.
Cancer 2009;115(10):2147-54.
2009: Wierda William G; O'Brien Susan; Wang Xuemei; Faderl Stefan; Ferrajoli Alessandra; Do Kim-Anh; Garcia-Manero Guillermo; Cortes Jorge; Thomas Deborah; Koller Charles; Burger Jan; Lerner Susan; Kantarjian Hagop; Keating Michael
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(10):1637-43.
2009: Lin Katherine I; Tam Constantine S; Keating Michael J; Wierda William G; O'Brien Susan; Lerner Susan; Coombes Kevin R; Schlette Ellen; Ferrajoli Alessandra; Barron Lynn L; Kipps Thomas J; Rassenti Laura; Faderl Stefan; Kantarjian Hagop; Abruzzo Lynne V
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
Blood 2009;113(14):3168-71.
2009: Jabbour Elias; Kantarjian Hagop M; Jones Dan; Shan Jenny; O'Brien Susan; Reddy Neeli; Wierda William G; Faderl Stefan; Garcia-Manero Guillermo; Verstovsek Srdan; Rios Mary Beth; Cortes Jorge
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
Blood 2009;113(10):2154-60.
2009: Faderl S; Ferrajoli A; Frankfurt O; Pettitt A
Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(3):457-66.
2009: Ravandi Farhad; Estey Eli; Jones Dan; Faderl Stefan; O'Brien Susan; Fiorentino Jackie; Pierce Sherry; Blamble Deborah; Estrov Zeev; Wierda William; Ferrajoli Alessandra; Verstovsek Srdan; Garcia-Manero Guillermo; Cortes Jorge; Kantarjian Hagop
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(4):504-10.
2009: Verma Dushyant; O'Brien Susan; Thomas Deborah; Faderl Stefan; Koller Charles; Pierce Sherry; Kebriaei Partow; Garcia-Manero Guillermo; Cortes Jorge; Kantarjian Hagop; Ravandi Farhad
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
Cancer 2009;115(1):101-6.
2009: O'Brien Susan M; Claxton David F; Crump Michael; Faderl Stefan; Kipps Thomas; Keating Michael J; Viallet Jean; Cheson Bruce D
Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.
Blood 2009;113(2):299-305.
2009: Sekeres Mikkael A; Elson Paul; Kalaycio Matt E; Advani Anjali S; Copelan Edward A; Faderl Stefan; Kantarjian Hagop M; Estey Elihu
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.
Blood 2009;113(1):28-36.
2009: Raza Azra; Galili Naomi; Callander Natalie; Ochoa Leonel; Piro Lawrence; Emanuel Peter; Williams Stephanie; Burris Howard; Faderl Stefan; Estrov Zeev; Curtin Peter; Larson Richard A; Keck James G; Jones Marsha; Meng Lisa; Brown Gail L
Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra(R), TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome.
Journal of hematology & oncology 2009;2():20.
2008: Gardner Alison; Mattiuzzi Gloria; Faderl Stefan; Borthakur Gautam; Garcia-Manero Guillermo; Pierce Sherry; Brandt Mark; Estey Elihu
Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(35):5684-8.
2008: Borthakur Gautam; Kantarjian Hagop; Wang Xuemei; Plunkett William K; Gandhi Varsha V; Faderl Stefan; Garcia-Manero Guillermo; Ravandi Farhad; Pierce Sherry; Estey Elihu H
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
Cancer 2008;113(11):3181-5.
2008: O'Brien Susan; Thomas Deborah; Ravandi Farhad; Faderl Stefan; Cortes Jorge; Borthakur Gautum; Pierce Sherry; Garcia-Manero Guillermo; Kantarjian Hagop M
Outcome of adults with acute lymphocytic leukemia after second salvage therapy.
Cancer 2008;113(11):3186-91.
2008: Kantarjian Hagop; O'Brien Susan; Cortes Jorge; Wierda William; Faderl Stefan; Garcia-Manero Guillermo; Issa Jean-Pierre; Estey Elihu; Keating Michael; Freireich Emil J
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.
Cancer 2008;113(7 Suppl):1933-52.
2008: Faderl Stefan; Ferrajoli Alessandra; Wierda William; Huang Xuelin; Verstovsek Srdan; Ravandi Farhad; Estrov Zeev; Borthakur Gautam; Kwari Monica; Kantarjian Hagop M
Clofarabine combinations as acute myeloid leukemia salvage therapy.
Cancer 2008;113(8):2090-6.
2008: O'Brien Susan; Thomas Deborah A; Ravandi Farhad; Faderl Stefan; Pierce Sherry; Kantarjian Hagop
Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.
Cancer 2008;113(8):2097-101.
2008: Yanada Masamitsu; Borthakur Gautam; Garcia-Manero Guillermo; Ravandi Farhad; Faderl Stefan; Pierce Sherry; Kantarjian Hagop; Estey Elihu
Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.
Leukemia research 2008;32(10):1505-9.
2008: Aribi Ahmed; Kantarjian Hagop; Koller Charles; Thomas Deborah; Faderl Stefan; Garcia-Manero Guillermo; Cortes Jorge
The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Cancer 2008;113(6):1338-43.
2008: Faderl Stefan; Ravandi Farhad; Huang Xuelin; Garcia-Manero Guillermo; Ferrajoli Alessandra; Estrov Zeev; Borthakur Gautam; Verstovsek Srdan; Thomas Deborah A; Kwari Monica; Kantarjian Hagop M
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Blood 2008;112(5):1638-45.
2008: Stock Wendy; Undevia Samir D; Bivins Carol; Ravandi Farhad; Odenike Olatoyosi; Faderl Stefan; Rich Elizabeth; Borthakur Gautam; Godley Lucy; Verstovsek Srdan; Artz Andrew; Wierda William; Larson Richard A; Zhang Yanming; Cortes Jorge; Ratain Mark J; Giles Francis J
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
Investigational new drugs 2008;26(4):331-8.
2008: Borthakur Gautam; Alvarado Yesid; Ravandi-Kashani Farhad; Cortes Jorge; Estrov Zeev; Faderl Stefan; Ivy Percy; Bueso-Ramos Carlos; Nebiyou Bekele B; Giles Francis
Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies.
Cancer 2008;113(2):360-6.
2008: Verstovsek Srdan; Tefferi Ayalew; Cortes Jorge; O'Brien Susan; Garcia-Manero Guillermo; Pardanani Animesh; Akin Cem; Faderl Stefan; Manshouri Taghi; Thomas Deborah; Kantarjian Hagop
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):3906-15.
2008: Ferrajoli Alessandra; Lee Bang-Ning; Schlette Ellen J; O'Brien Susan M; Gao Hui; Wen Sijin; Wierda William G; Estrov Zeev; Faderl Stefan; Cohen Evan N; Li Changping; Reuben James M; Keating Michael J
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.
Blood 2008;111(11):5291-7.
2008: Borthakur Gautam; Ahdab Samih El; Ravandi Farhad; Faderl Stefan; Ferrajoli Alessandra; Newman Beth; Issa Jean-Pierre; Kantarjian Hagop
Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.
Leukemia & lymphoma 2008;49(4):690-5.
2008: Ferrajoli Alessandra; Wierda William G; LaPushin Ruth; O'Brien Susan M; Faderl Stefan; Browning Mary L; Keating Michael J
Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
European journal of haematology 2008;80(4):296-8.
2008: Faderl Stefan; Gandhi Varsha; Kantarjian Hagop M
Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia.
Current opinion in hematology 2008;15(2):101-7.
2008: Garcia-Manero G; Shan J; Faderl S; Cortes J; Ravandi F; Borthakur G; Wierda W G; Pierce S; Estey E; Liu J; Huang X; Kantarjian H
A prognostic score for patients with lower risk myelodysplastic syndrome.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(3):538-43.
2008: Kantarjian Hagop; O'Brien Susan; Shan Jianqin; Huang Xuelin; Garcia-Manero Guillermo; Faderl Stefan; Ravandi-Kashani Farhad; Verstovsek Srdan; Beth Rios Mary; Cortes Jorge
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
Cancer 2008;112(4):837-45.
2008: Garcia-Manero Guillermo; Yang Hui; Bueso-Ramos Carlos; Ferrajoli Alessandra; Cortes Jorge; Wierda William G; Faderl Stefan; Koller Charles; Morris Gail; Rosner Gary; Loboda Andrey; Fantin Valeria R; Randolph Sophia S; Hardwick James S; Reilly John F; Chen Cong; Ricker Justin L; Secrist J Paul; Richon Victoria M; Frankel Stanley R; Kantarjian Hagop M
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Blood 2008;111(3):1060-6.
2007: Ferrajoli Alessandra; Faderl Stefan; Van Quin; Koch Patricia; Harris David; Liu Zhiming; Hazan-Halevy Inbal; Wang Yongtao; Kantarjian Hagop M; Priebe Waldemar; Estrov Zeev
WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.
Cancer research 2007;67(23):11291-9.
2007: Borthakur Gautam; Lin E; Faderl Stefan; Ferrajoli Alessandra; Wierda William; Giles Francis; Browning Mary L; Kantarjian Hagop; Keating Michael; O'Brien Susan
Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies.
Cancer 2007;110(11):2478-83.
2007: Jabbour Elias; Kantarjian Hagop; Cortes Jorge; Thomas Deborah; Garcia-Manero Guillermo; Ferrajoli Alessandra; Faderl Stefan; Richie Mary Ann; Beran Miloslav; Giles Francis; Verstovsek Srdan
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
Cancer 2007;110(9):2012-8.
2007: Cortes Jorge; Quintás-Cardama Alfonso; Garcia-Manero Guillermo; O'Brien Susan; Jones Dan; Faderl Stefan; Ebarb Theresa; Giles Francis; Thomas Deborah; Kantarjian Hagop
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
Cancer 2007;110(9):2000-6.
2007: Tsimberidou Apostolia M; Wen Sijin; O'Brien Susan; McLaughlin Peter; Wierda William G; Ferrajoli Alessandra; Faderl Stefan; Manning John; Lerner Susan; Mai Chinh V; Rodriguez Alma M; Hess Mark; Do Kim-Anh; Freireich Emil J; Kantarjian Hagop M; Medeiros L Jeffrey; Keating Michael J
Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(29):4648-56.
2007: Tam Constantine S; O'Brien Susan; Lerner Susan; Khouri I; Ferrajoli A; Faderl S; Browning M; Tsimberidou Apostolia M; Kantarjian Hagop; Wierda William G
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.
Leukemia & lymphoma 2007;48(10):1931-9.
2007: Kantarjian Hagop M; Jeha Sima; Gandhi Varsha; Wess Michael; Faderl Stefan
Clofarabine: past, present, and future.
Leukemia & lymphoma 2007;48(10):1922-30.
2007: Soriano Andres O; Yang Hui; Faderl Stefan; Estrov Zeev; Giles Francis; Ravandi Farhad; Cortes Jorge; Wierda William G; Ouzounian Souzanne; Quezada Andres; Pierce Sherry; Estey Elihu H; Issa Jean-Pierre J; Kantarjian Hagop M; Garcia-Manero Guillermo
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Blood 2007;110(7):2302-8.
2007: Yanada Masamitsu; Huang Xuelin; Garcia-Manero Guillermo; O'brien Susan; Ravandi Farhad; Borthakur Gautam; Faderl Stefan; Issa Jean-Pierre; Kantarjian Hagop; Estey Elihu
Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
British journal of haematology 2007;138(4):555-7.
2007: Aribi Ahmed; Bueso-Ramos Carlos; Estey Eli; Estrov Zeev; O'Brien Susan; Giles Francis; Faderl Stefan; Thomas Deborah; Kebriaei Partow; Garcia-Manero Guillermo; Pierce Sherry; Cortes Jorge; Kantarjian Hagop; Ravandi Farhad
Biphenotypic acute leukaemia: a case series.
British journal of haematology 2007;138(2):213-6.
2007: Aribi Ahmed; Huh Yang; Keating Michael; O'brien Susan; Ferrajoli Alessandra; Faderl Stefan; Wierda William; Kantarjian Hagop; Ravandi Farhad
T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.
Leukemia research 2007;31(7):939-45.
2007: Wierda William G; O'Brien Susan; Wang Xuemei; Faderl Stefan; Ferrajoli Alessandra; Do Kim-Anh; Cortes Jorge; Thomas Deborah; Garcia-Manero Guillermo; Koller Charles; Beran Miloslav; Giles Francis; Ravandi Farhad; Lerner Susan; Kantarjian Hagop; Keating Michael
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
Blood 2007;109(11):4679-85.
2007: Kantarjian Hagop; O'Brien Susan; Talpaz Moshe; Borthakur Gautam; Ravandi Farhad; Faderl Stefan; Verstovsek Srdan; Rios Mary Beth; Shan Jianqin; Giles Francis; Cortes Jorge
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
Cancer 2007;109(8):1556-60.
2007: Aribi Ahmed; Kantarjian Hagop M; Estey Elihu H; Koller Charles A; Thomas Deborah A; Kornblau Steven M; Faderl Stefan H; Laddie Nakia M; Garcia-Manero Guillermo; Cortes Jorge E
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Cancer 2007;109(7):1355-9.
2007: Kornblau Steven M; Banker Deborah E; Stirewalt Derek; Shen Danny; Lemker Elizabeth; Verstovsek Srdan; Estrov Zeev; Faderl Stefan; Cortes Jorge; Beran Miloslav; Jackson C Ellen; Chen Wenjing; Estey Elihu; Appelbaum Frederick R
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.
Blood 2007;109(7):2999-3006.
2007: Quintás-Cardama Alfonso; Kantarjian Hagop; Garcia-Manero Guillermo; O'Brien Susan; Faderl Stefan; Ravandi Farhad; Giles Francis; Thomas Deborah; Wierda William; Cortes Jorge
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
Leukemia & lymphoma 2007;48(2):283-9.
2007: Giles Francis J; Borthakur Gautam; Ravandi Farhad; Faderl Stefan; Verstovsek Srdan; Thomas Deborah; Wierda William; Ferrajoli Alessandra; Kornblau Steven; Pierce Sherry; Albitar Maher; Cortes Jorge; Kantarjian Hagop
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
British journal of haematology 2007;136(4):624-7.
2007: Quintás-Cardama Alfonso; Kantarjian Hagop; Garcia-Manero Guillermo; O'Brien Susan; Faderl Stefan; Estrov Zeev; Giles Francis; Murgo Anthony; Ladie Nakia; Verstovsek Srdan; Cortes Jorge
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Cancer 2007;109(2):248-55.
2007: Roboz Gail J; Giles Francis J; Ritchie Ellen K; Allen-Bard Sandra; Curcio Tania J; Wilkes Meredith A; Park S Lani; Kantarjian Hagop M; Faderl Stefan; Ravandi Farhad; Kelner Michael J; Feldman Eric J
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):10-5.
2007: Giles Francis; Rizzieri David; Karp Judith; Vey Norbert; Ravandi Farhad; Faderl Stefan; Khan Khuda Dad; Verhoef Gregor; Wijermans Pierre; Advani Anjali; Roboz Gail; Kantarjian Hagop; Bilgrami Syed Fazl Ali; Ferrant Augustin; Daenen Simon M G J; Karsten Verena; Cahill Ann; Albitar Maher; Mufti Ghulam; O'Brien Susan
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):25-31.
2007: Kantarjian Hagop; Oki Yasuhiro; Garcia-Manero Guillermo; Huang Xuelin; O'Brien Susan; Cortes Jorge; Faderl Stefan; Bueso-Ramos Carlos; Ravandi Farhad; Estrov Zeev; Ferrajoli Alessandra; Wierda William; Shan Jianqin; Davis Jan; Giles Francis; Saba Hussain I; Issa Jean-Pierre J
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Blood 2007;109(1):52-7.
2007: Faderl Stefan; Ferrajoli Alessandra; Harris David; Van Quin; Kantarjian Hagop M; Estrov Zeev
Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells.
Leukemia research 2007;31(1):91-5.
2006: Giles Francis; Verstovsek Srdan; Faderl Stefan; Vey Norbert; Karp Judy; Roboz Gail; Khan Khuda Dan; Cooper Maureen; Bilgrami Syed Fazl Ali; Ferrant Augustin; Daenen Simon; Karsten Verena; Cahill Ann; Albitar Maher; Kantarjian Hagop; O'Brien Susan; Feldman Eric
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.
Leukemia research 2006;30(12):1591-5.
2006: Garcia-Manero Guillermo; Kantarjian Hagop M; Sanchez-Gonzalez Blanca; Yang Hui; Rosner Gary; Verstovsek Srdan; Rytting Michael; Wierda William G; Ravandi Farhad; Koller Charles; Xiao Lianchun; Faderl Stefan; Estrov Zeev; Cortes Jorge; O'brien Susan; Estey Elihu; Bueso-Ramos Carlos; Fiorentino Jackie; Jabbour Elias; Issa Jean-Pierre
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Blood 2006;108(10):3271-9.
2006: Quintas-Cardama Alfonso; Kantarjian Hagop; O'Brien Susan; Jabbour Elias; Giles Francis; Ravandi Farhad; Faderl Stefan; Pierce Sherry; Shan Jenny; Verstovsek Srdan; Cortes Jorge
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Cancer 2006;107(7):1525-9.
2006: Ferrajoli Alessandra; Faderl Stefan; Keating Michael J
Monoclonal antibodies in chronic lymphocytic leukemia.
Expert review of anticancer therapy 2006;6(9):1231-8.
2006: Thompson Michael A; Dyson Senait W; Faderl Stefan
Sweet's syndrome in chronic lymphocytic leukemia associated with neutropenic fever and granulocyte colony stimulation factor.
American journal of hematology 2006;81(9):703-5.
2006: Faderl Stefan; Rai Kanti; Gribben John; Byrd John C; Flinn Ian W; O'Brien Susan; Sheng Shihong; Esseltine Dixie-Lee; Keating Michael J
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Cancer 2006;107(5):916-24.
2006: Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Jones Daniel; Giles Francis; Garcia-Manero Guillermo; Faderl Stefan; Ravandi Farhad; Rios Mary Beth; Shan Jianqin; Cortes Jorge
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Blood 2006;108(6):1835-40.
2006: Kim K B; Faderl S; Hwang C S; Khuri F R
Chronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literature.
Journal of clinical pharmacy and therapeutics 2006;31(4):401-6.
2006: Yee Karen W L; Cortes Jorge; Ferrajoli Alessandra; Garcia-Manero Guillermo; Verstovsek Srdan; Wierda William; Thomas Deborah; Faderl Stefan; King Ivan; O'brien Susan M; Jeha Sima; Andreeff Michael; Cahill Ann; Sznol Mario; Giles Francis J
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
Leukemia research 2006;30(7):813-22.
2006: Faderl Stefan; Verstovsek Srdan; Cortes Jorge; Ravandi Farhad; Beran Miloslav; Garcia-Manero Guillermo; Ferrajoli Alessandra; Estrov Zeev; O'Brien Susan; Koller Charles; Giles Francis J; Wierda William; Kwari Monica; Kantarjian Hagop M
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
Blood 2006;108(1):45-51.
2006: Tibes Raoul; Keating Michael J; Ferrajoli Alessandra; Wierda William; Ravandi Farhad; Garcia-Manero Guillermo; O'Brien Susan; Cortes Jorge; Verstovsek Srdan; Browning Mary L; Faderl Stefan
Activity of alemtuzumab in patients with CD52-positive acute leukemia.
Cancer 2006;106(12):2645-51.
2006: Ravandi Farhad; Jorgensen Jeffrey L; O'Brien Susan M; Verstovsek Srdan; Koller Charles A; Faderl Stefan; Giles Francis J; Ferrajoli Alessandra; Wierda William G; Odinga Shirley; Huang Xuelin; Thomas Deborah A; Freireich Emil J; Jones Dan; Keating Michael J; Kantarjian Hagop M
Eradication of minimal residual disease in hairy cell leukemia.
Blood 2006;107(12):4658-62.
2006: Thomas Deborah A; Giles Francis J; Albitar Maher; Cortes Jorge E; Verstovsek Srdan; Faderl Stefan; O'Brien Susan M; Garcia-Manero Guillermo; Keating Michael J; Pierce Sherry; Zeldis Jerome; Kantarjian Hagop M
Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Cancer 2006;106(9):1974-84.
2006: Estey Elihu; Garcia-Manero Guillermo; Ferrajoli Alessandra; Faderl Stefan; Verstovsek Srdan; Jones Dan; Kantarjian Hagop
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Blood 2006;107(9):3469-73.
2006: Thomas Deborah A; Faderl Stefan; O'Brien Susan; Bueso-Ramos Carlos; Cortes Jorge; Garcia-Manero Guillermo; Giles Francis J; Verstovsek Srdan; Wierda William G; Pierce Sherry A; Shan Jianqin; Brandt Mark; Hagemeister Fredrick B; Keating Michael J; Cabanillas Fernando; Kantarjian Hagop
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Cancer 2006;106(7):1569-80.
2006: Cortes Jorge E; Talpaz Moshe; O'Brien Susan; Faderl Stefan; Garcia-Manero Guillermo; Ferrajoli Alessandra; Verstovsek Srdan; Rios Mary B; Shan Jenny; Kantarjian Hagop M
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
Cancer 2006;106(6):1306-15.
2006: Ault Patricia; Kantarjian Hagop; O'Brien Susan; Faderl Stefan; Beran Miloslav; Rios Mary Beth; Koller Charles; Giles Francis; Keating Michael; Talpaz Moshe; Cortes Jorge
Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(7):1204-8.
2006: Kantarjian Hagop; O'brien Susan; Cortes Jorge; Giles Francis; Faderl Stefan; Jabbour Elias; Garcia-Manero Guillermo; Wierda William; Pierce Sherry; Shan Jianqin; Estey Elihu
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.
Cancer 2006;106(5):1090-8.
2006: Patel Sandip P; Garcia-Manero Guillermo; Ferrajoli Alexandra; Faderl Stefan; Verstovek Serge; Kantarjian Hagop; Estey Elihu
Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
Leukemia research 2006;30(3):362-3.
2006: Oki Yasuhiro; Kantarjian Hagop M; Zhou Xian; Cortes Jorge; Faderl Stefan; Verstovsek Srdan; O'Brien Susan; Koller Charles; Beran Miloslav; Bekele B Nebiyou; Pierce Sherry; Thomas Deborah; Ravandi Farhad; Wierda William G; Giles Francis; Ferrajoli Alessandra; Jabbour Elias; Keating Michael J; Bueso-Ramos Carlos E; Estey Elihu; Garcia-Manero Guillermo
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Blood 2006;107(3):880-4.
2006: Mattiuzzi Gloria N; Alvarado Gladys; Giles Francis J; Ostrosky-Zeichner Luis; Cortes Jorge; O'brien Susan; Verstovsek Srdan; Faderl Stefan; Zhou Xian; Raad Issam I; Bekele B Nebiyou; Leitz G J; Lopez-Roman Ivonne; Estey Elihu H
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies.
Antimicrobial agents and chemotherapy 2006;50(1):143-7.
2006: Wierda William; O'brien Susan; Faderl Stefan; Ferrajoli Alessandra; Wang Xuemei; Do Kim-Anh; Garcia-Manero Guillermo; Thomas Deborah; Cortes Jorge; Ravandi-Kashani Farhad; Giles Francis; Lerner Susan; Kantarjian Hagop; Keating Michael
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
Cancer 2006;106(2):337-45.
2006: Borthakur Gautam; Kantarjian Hagop; Daley George; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Giles Francis; Faderl Stefan; Sugrue Mary; Cortes Jorge
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
Cancer 2006;106(2):346-52.
2006: Thomas Deborah A; Sarris Andreas H; Cortes Jorge; Faderl Stefan; O'Brien Susan; Giles Francis J; Garcia-Manero Guillermo; Rodriguez Maria A; Cabanillas Fernando; Kantarjian Hagop
Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
Cancer 2006;106(1):120-7.
2006: Ravandi Farhad; Faderl Stefan
Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin.
Leukemia research 2006;30(1):103-5.
2006: Faderl Stefan; O'Brien Susan; Keating Michael J
Monoclonal antibody combinations in CLL: evolving strategies.
Best practice & research. Clinical haematology 2006;19(4):781-93.
2005: Faderl S; Coutré S; Byrd J C; Dearden C; Denes A; Dyer M J S; Gregory S A; Gribben J G; Hillmen P; Keating M; Rosen S; Venugopal P; Rai K
The evolving role of alemtuzumab in management of patients with CLL.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(12):2147-52.
2005: Gandhi Varsha; Kilpatrick John M; Plunkett William; Ayres Mary; Harman Leigh; Du Min; Bantia Shanta; Davisson Jan; Wierda William G; Faderl Stefan; Kantarjian Hagop; Thomas Deborah
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
Blood 2005;106(13):4253-60.
2005: Faderl Stefan; Do Kim-Anh; Johnson Marcella M; Keating Michael; O'brien Susan; Jilani Iman; Ferrajoli Alessandra; Ravandi-Kashani Farhad; Aguilar Christine; Dey Amanda; Thomas Deborah A; Giles Francis J; Kantarjian Hagop M; Albitar Maher
Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia.
Blood 2005;106(13):4303-7.
2005: Ravandi Farhad; O'Brien Susan; Jones Dan; Lerner Susan; Faderl Stefan; Ferrajoli Alessandra; Wierda William; Garcia-Manero Guillermo; Thomas Deborah; Koller Charles; Verstovsek Srdan; Giles Francis; Cortes Jorge; Herling Marco; Kantarjian Hagop; Keating Michael
T-cell prolymphocytic leukemia: a single-institution experience.
Clinical lymphoma & myeloma 2005;6(3):234-9.
2005: Jabbour Elias J; Faderl Stefan; Kantarjian Hagop M
Adult acute lymphoblastic leukemia.
Mayo Clinic proceedings. Mayo Clinic 2005;80(11):1517-27.
2005: Giles Francis; Verstovsek Srdan; Thomas Deborah; Gerson Stanton; Cortes Jorge; Faderl Stefan; Ferrajoli Alessandra; Ravandi Farhad; Kornblau Steven; Garcia-Manero Guillermo; Jabbour Elias; O'Brien Susan; Karsten Verena; Cahill Ann; Yee Karen; Albitar Maher; Sznol Mario; Kantarjian Hagop
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7817-24.
2005: Yee Karen W L; Hagey Anne; Verstovsek Srdan; Cortes Jorge; Garcia-Manero Guillermo; O'Brien Susan M; Faderl Stefan; Thomas Deborah; Wierda William; Kornblau Steven; Ferrajoli Alessandra; Albitar Maher; McKeegan Evelyn; Grimm David R; Mueller Toby; Holley-Shanks Rhonda R; Sahelijo Leonardo; Gordon Gary B; Kantarjian Hagop M; Giles Francis J
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(18):6615-24.
2005: Kantarjian Hagop M; Bueso-Ramos Carlos E; Talpaz Moshe; O'Brien Susan; Giles Francis; Faderl Stefan; Wierda William; Rios Mary Beth; Shan Jianqin; Cortes Jorge
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
Cancer 2005;104(4):777-80.
2005: Faderl Stefan; Kantarjian Hagop M
Drug insight: emerging new drugs in the treatment of myelodysplastic syndromes.
Nature clinical practice. Oncology 2005;2(7):348-55.
2005: Giles Francis J; Kantarjian Hagop M; Cortes Jorge E; Faderl Stephan; Verstovsek Srdan; Thomas Deborah; Garcia-Manero Guillermo; Wierda William; Ferrajoli Alessandra; Kornblau Stephen; Mattiuzzi Gloria N; Tsimberidou Apostolia M; Albitar Maher; O'Brien Susan M; Estey Elihu
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Leukemia research 2005;29(6):649-52.
2005: Keating Michael J; O'Brien Susan; Albitar Maher; Lerner Susan; Plunkett William; Giles Francis; Andreeff Michael; Cortes Jorge; Faderl Stefan; Thomas Deborah; Koller Charles; Wierda William; Detry Michelle A; Lynn Alice; Kantarjian Hagop
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4079-88.
2005: Wierda William; O'Brien Susan; Wen Sijin; Faderl Stefan; Garcia-Manero Guillermo; Thomas Deborah; Do Kim-Anh; Cortes Jorge; Koller Charles; Beran Miloslav; Ferrajoli Alessandra; Giles Francis; Lerner Susan; Albitar Maher; Kantarjian Hagop; Keating Michael
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4070-8.
2005: Faderl Stefan; Ferrajoli Alessandra; Harris David; Van Quin; Priebe Waldemar; Estrov Zeev
WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML).
Anticancer research 2005;25(3B):1841-50.
2005: Cortes Jorge; Talpaz Moshe; O'Brien Susan; Jones Dan; Luthra Rajyalakshmi; Shan Jenny; Giles Francis; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Rios Mary B; Kantarjian Hagop
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3425-32.
2005: Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Giles Francis; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Shan Jianqin; Rios Mary Beth; Champlin Richard; de Lima Marcos; Cortes Jorge
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
Cancer 2005;103(10):2099-108.
2005: Faderl Stefan; Gandhi Varsha; Keating Michael J; Jeha Sima; Plunkett William; Kantarjian Hagop M
The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog.
Cancer 2005;103(10):1985-95.
2005: Cortes Jorge; Faderl Stefan; Estey Elihu; Kurzrock Razelle; Thomas Deborah; Beran Miloslav; Garcia-Manero Guillermo; Ferrajoli Alessandra; Giles Francis; Koller Charles; O'Brien Susan; Wright John; Bai Stephen A; Kantarjian Hagop
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2805-12.
2005: Faderl Stefan; Gandhi Varsha; O'Brien Susan; Bonate Peter; Cortes Jorge; Estey Elihu; Beran Miloslav; Wierda William; Garcia-Manero Guillermo; Ferrajoli Alessandra; Estrov Zeev; Giles Francis J; Du Min; Kwari Monica; Keating Michael; Plunkett William; Kantarjian Hagop
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
Blood 2005;105(3):940-7.
2005: Faderl Stefan
Treatment algorithms in CLL.
Hematology (Amsterdam, Netherlands) 2005;10 Suppl 1():200-2.
2004: Hennessy Bryan; Giles Francis; Cortes Jorge; O'brien Susan; Ferrajoli Alessandra; Ossa Gladys; Garcia-Manero Guillermo; Faderl Stefan; Kantarjian Hagop; Verstovsek Srdan
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
American journal of hematology 2004;77(3):209-14.
2004: Kantarjian Hagop M; Cortes Jorge E; O'Brien Susan; Luthra Rajyalakshmi; Giles Francis; Verstovsek Srdan; Faderl Stefan; Thomas Deborah; Garcia-Manero Guillermo; Rios Mary Beth; Shan Jianqin; Jones Dan; Talpaz Moshe
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
Blood 2004;104(7):1979-88.
2004: Tsimberidou Apostolia-Maria; Estey Elihu; Whitman Gary J; Dryden Mark J; Ratnam Suresh; Pierce Sherry; Faderl Stefan; Giles Francis; Kantarjian Hagop M; Garcia-Manero Guillermo
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
Leukemia research 2004;28(9):991-4.
2004: Thomas Deborah A; O'Brien Susan; Cortes Jorge; Giles Francis J; Faderl Stefan; Verstovsek Srdan; Ferrajoli Alessandra; Koller Charles; Beran Miloslav; Pierce Sherry; Ha Chul S; Cabanillas Fernando; Keating Michael J; Kantarjian Hagop
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
Blood 2004;104(6):1624-30.
2004: Faderl Stefan; Kantarjian Hagop M
Novel therapies for myelodysplastic syndromes.
Cancer 2004;101(2):226-41.
2004: Verstovsek Srdan; Giles Francis J; O'Brien Susan; Faderl Stefan; Kantarjian Hagop M; Keating Michael J; Albitar Maher
Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia.
Leukemia research 2004;28(7):707-11.
2004: Faderl Stefan; Hochhaus Andreas; Hughes Timothy
Monitoring of minimal residual disease in chronic myeloid leukemia.
Hematology/oncology clinics of North America 2004;18(3):657-70, ix-x.
2004: Tsimberidou Apostolia-Maria; Medina Jorge; Cortes Jorge; Rios Adan; Bonnie Glisson; Faderl Stefan; Kantarjian Hagop; Garcia-Manero Guillermo
Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature.
Leukemia research 2004;28(6):657-60.
2004: Thomas Deborah A; Faderl Stefan; Cortes Jorge; O'Brien Susan; Giles Francis J; Kornblau Steven M; Garcia-Manero Guillermo; Keating Michael J; Andreeff Michael; Jeha Sima; Beran Miloslav; Verstovsek Srdan; Pierce Sherry; Letvak Laurie; Salvado August; Champlin Richard; Talpaz Moshe; Kantarjian Hagop
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Blood 2004;103(12):4396-407.
2004: Cortes Jorge; Thomas Deborah; Koller Charles; Giles Francis; Estey Elihu; Faderl Stefan; Garcia-Manero Guillermo; McConkey David; Ruiz Stacey L; Guerciolini Roberto; Wright John; Kantarjian Hagop
Phase I study of bortezomib in refractory or relapsed acute leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3371-6.
2004: Giles Francis; Thomas Deborah; Garcia-Manero Guillermo; Faderl Stefan; Cortes Jorge; Verstovsek Srdan; Ferrajoli Alessandra; Jeha Sima; Beran Miloslav; Koller Charles; Andreeff Michael; Cahill Ann; Clairmont Caroline; Sznol Mario; Kantarjian Hagop
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(9):2908-17.
2004: Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Verstovsek Srdan; Giles Francis; Rios Mary Beth; Shan Jianqin; Letvak Laurie; Thomas Deborah; Faderl Stefan; Ferrajoli Alessandra; Cortes Jorge
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Blood 2004;103(8):2873-8.
2004: Kurzrock Razelle; Albitar Maher; Cortes Jorge E; Estey Elihu H; Faderl Stefan H; Garcia-Manero Guillermo; Thomas Deborah A; Giles Francis J; Ryback Mary Ellen; Thibault Alain; De Porre P; Kantarjian Hagop M
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(7):1287-92.
2004: Keating Michael; Coutré Stephen; Rai Kanti; Osterborg Anders; Faderl Stefan; Kennedy Ben; Kipps Tom; Bodey Gerald; Byrd John C; Rosen Steven; Dearden Claire; Dyer Martin J S; Hillmen Peter
Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia.
Clinical lymphoma 2004;4(4):220-7.
2004: Issa Jean-Pierre J; Garcia-Manero Guillermo; Giles Francis J; Mannari Rajan; Thomas Deborah; Faderl Stefan; Bayar Emel; Lyons John; Rosenfeld Craig S; Cortes Jorge; Kantarjian Hagop M
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Blood 2004;103(5):1635-40.
2004: Mattiuzzi Gloria N; Kantarjian Hagop; Faderl Stefan; Lim JoAnn; Kontoyiannis Dimitrios; Thomas Deborah; Wierda William; Raad Isaam; Garcia-Manero Guillermo; Zhou Xian; Ferrajoli Alexandra; Bekele Nebiyou; Estey Elihu
Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
Cancer 2004;100(3):581-9.
2004: Mattiuzzi Gloria N; Kantarjian Hagop; O'Brien Susan; Kontoyiannis Dimitrios P; Giles Francis; Zhou Xian; Lim JoAnn; Bekele B Nebiyou; Faderl Stefan; Cortes Jorge; Pierce Sherry; Leitz Gerhard J; Raad Issam; Estey Elihu
Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
Cancer 2004;100(3):568-73.
2004: Faderl Stefan; Estrov Zeev
Hematopoietic recovery following induction therapy of acute leukemias: prognostic implications and a new look at the definition of remission.
Leukemia & lymphoma 2004;45(1):67-71.
2004: Zangari Maurizio; Anaissie Elias; Stopeck Alison; Morimoto Alyssa; Tan Nguyen; Lancet Jeffrey; Cooper Maureen; Hannah Alison; Garcia-Manero Guillermo; Faderl Stephan; Kantarjian Hagop; Cherrington Julie; Albitar Maher; Giles Francis J
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):88-95.
2004: Kantarjian Hagop; O'Brien Susan; Cortes Jorge; Giles Francis; Shan Jianqin; Rios Mary Beth; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Wierda William; Kornblau Steven; Ferrajoli Alessandra; Keating Michael; Talpaz Moshe
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):68-75.
2004: Sneed Thomas B; Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Rios Mary Beth; Bekele B Nebiyou; Zhou Xian; Resta Debra; Wierda William; Faderl Stefan; Giles Francis; Cortes Jorge E
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Cancer 2004;100(1):116-21.
2003: Gandhi Varsha; Kantarjian Hagop; Faderl Stefan; Bonate Peter; Du Min; Ayres Mary; Rios Mary Beth; Keating Michael J; Plunkett William
Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(17):6335-42.
2003: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge; Giles Francis J; Rios Mary Beth; Shan Jianqin; Faderl Stefan; Garcia-Manero Guillermo; Ferrajoli Alessandra; Verstovsek Srdan; Wierda William; Keating Michael; Talpaz Moshe
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Cancer 2003;98(12):2636-42.
2003: Tsimberidou Apostolia M; Estey Elihu; Cortes Jorge E; Garcia-Manero Guillermo; Faderl Stefan; Verstovsek Srdan; Thomas Deborah A; Ferrajoli Alessandra; Keating Michael J; O'Brien Susan; Kantarjian Hagop M; Giles Francis J
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
Cancer chemotherapy and pharmacology 2003;52(6):449-52.
2003: Giles Francis J; Feldman Eric J; Roboz Gail J; Larson Richard A; Mamus Steven W; Cortes Jorge E; Verstovsek Srdan; Faderl Stefan; Talpaz Moshe; Beran Miloslav; Albitar Maher; O'Brien Susan M; Kantarjian Hagop M
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
Leukemia research 2003;27(12):1091-6.
2003: Giles Francis J; Fracasso Paula M; Kantarjian Hagop M; Cortes Jorge E; Brown Randy A; Verstovsek Srdan; Alvarado Yesid; Thomas Deborah A; Faderl Stefan; Garcia-Manero Guillermo; Wright Lisa P; Samson Tom; Cahill Ann; Lambert Paula; Plunkett William; Sznol Mario; DiPersio John F; Gandhi Varsha
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
Leukemia research 2003;27(12):1077-83.
2003: Thomas Deborah A; O'Brien Susan; Bueso-Ramos Carlos; Faderl Stefan; Keating Michael J; Giles Francis J; Cortes Jorge; Kantarjian Hagop M
Rituximab in relapsed or refractory hairy cell leukemia.
Blood 2003;102(12):3906-11.
2003: Thomas Deborah A; Estey Elihu; Giles Francis J; Faderl Stefan; Cortes Jorge; Keating Michael; O'Brien Susan; Albitar Maher; Kantarjian Hagop
Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia.
British journal of haematology 2003;123(3):436-41.
2003: Pahler Jessica C; Ruiz Stacey; Niemer Irina; Calvert Leslie R; Andreeff Michael; Keating Michael; Faderl Stefan; McConkey David J
Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(12):4570-7.
2003: Kantarjian Hagop; O'Brien Susan; Cortes Jorges; Shan Jianqin; Giles Francis; Garcia-Manero Guillermo; Verstovsek Srdan; Faderl Stefan; Rios Mary Beth; Talpaz Moshe
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Cancer 2003;98(7):1430-7.
2003: Faderl Stefan; Jeha Sima; Kantarjian Hagop M
The biology and therapy of adult acute lymphoblastic leukemia.
Cancer 2003;98(7):1337-54.
2003: Tsimberidou Apostolia; Cortes Jorge; Thomas Deborah; Garcia-Manero Guillermo; Verstovsek Srdan; Faderl Stephan; Albitar Maher; Kantarjian Hagop; Estey Elihu; Giles Francis J
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Leukemia research 2003;27(10):893-7.
2003: Kantarjian Hagop; Gandhi Varsha; Cortes Jorge; Verstovsek Srdan; Du Min; Garcia-Manero Guillermo; Giles Francis; Faderl Stefan; O'Brien Susan; Jeha Sima; Davis Jan; Shaked Zeev; Craig Adam; Keating Michael; Plunkett William; Freireich Emil J
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
Blood 2003;102(7):2379-86.
2003: Cortes Jorge; Talpaz Moshe; O'Brien Susan; Giles Francis; Beth Rios Mary; Shan Jianquin; Faderl Stefan; Garcia-Manero Guillermo; Ferrajoli Alessandra; Wierda William; Kantarjian Hagop
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 2003;98(6):1105-13.
2003: O'Brien Susan; Giles Francis; Talpaz Moshe; Cortes Jorge; Rios Mary Beth; Shan Jianqin; Thomas Deborah; Andreeff Michael; Kornblau Steven; Faderl Stefan; Garcia-Manero Guillermo; White Kevin; Mallard Susie; Freireich Emil; Kantarjian Hagop M
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
Cancer 2003;98(5):888-93.
2003: Ferrajoli Alessandra; O'Brien Susan M; Cortes Jorge E; Giles Francis J; Thomas Deborah A; Faderl Stefan; Kurzrock Razelle; Lerner Susan; Kontoyiannis Dimitrios P; Keating Michael J
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
Cancer 2003;98(4):773-8.
2003: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge; Giles Francis J; Faderl Stefan; Issa Jean-Pierre; Garcia-Manero Guillermo; Rios Mary Beth; Shan Jianqin; Andreeff Michael; Keating Michael; Talpaz Moshe
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
Cancer 2003;98(3):522-8.
2003: Garcia-Manero Guillermo; Faderl Stefan; O'Brien Susan; Cortes Jorge; Talpaz Moshe; Kantarjian Hagop M
Chronic myelogenous leukemia: a review and update of therapeutic strategies.
Cancer 2003;98(3):437-57.
2003: Estrov Zeev; Shishodia Shishir; Faderl Stefan; Harris David; Van Quin; Kantarjian Hagop M; Talpaz Moshe; Aggarwal Bharat B
Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells.
Blood 2003;102(3):987-95.
2003: Verstovsek Srdan; Lunin Scott; Kantarjian Hagop; Manshouri Taghi; Faderl Stefan; Cortes Jorge; Giles Francis; Albitar Maher
Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia.
Leukemia research 2003;27(7):661-9.
2003: Faderl Stefan; Harris David; Van Quin; Kantarjian Hagop M; Talpaz Moshe; Estrov Zeev
Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia.
Blood 2003;102(2):630-7.
2003: Cortes Jorge; Giles Francis; O'Brien Susan; Thomas Deborah; Garcia-Manero Guillermo; Rios Mary Beth; Faderl Stefan; Verstovsek Srdan; Ferrajoli Alessandra; Freireich Emil J; Talpaz Moshe; Kantarjian Hagop
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
Blood 2003;102(1):83-6.
2003: Garcia-Manero Guillermo; Talpaz Moshe; Giles Francis J; Cortes Jorge; Faderl Stefan; O'Brien Susan; Thomas Deborah; Verstovsek Srdan; Beth Rios Mary; Shan Jianquin; Ferrajoli Alessandra; Wierda William; Kantarjian Hagop M
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
Cancer 2003;97(12):3010-6.
2003: Cortes Jorge; Giles Francis; O'Brien Susan; Thomas Deborah; Albitar Maher; Rios Mary Beth; Talpaz Moshe; Garcia-Manero Guillermo; Faderl Stefan; Letvak Laurie; Salvado August; Kantarjian Hagop
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cancer 2003;97(11):2760-6.
2003: Tsimberidou A-M; Kantarjian H M; Estey E; Cortes J E; Verstovsek S; Faderl S; Thomas D A; Garcia-Manero G; Ferrajoli A; Manning J T; Keating M J; Albitar M; O'Brien S; Giles F J
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(6):1100-3.
2003: Estey Elihu; Giles Francis; Cortes Jorge; Beran Miloslav; Verstovsek Srdan; Garcia-Manero Guillermo; Faderl Stefan; Kantarjian Hagop
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.
Leukemia research 2003;27(6):475-9.
2003: Faderl Stefan; Estrov Zeev
Commentary: effect of flavonoids on normal and leukemic cells.
Leukemia research 2003;27(6):471-3.
2003: Giles Francis J; Kantarjian Hagop M; Cortes Jorge E; Garcia-Manero Guillermo; Verstovsek Srdan; Faderl Stefan; Thomas Deborah A; Ferrajoli Alessandra; O'Brien Susan; Wathen Jay K; Xiao Lian-Chun; Berry Donald A; Estey Elihu H
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1722-7.
2003: Cortes Jorge E; Talpaz Moshe; Giles Francis; O'Brien Susan; Rios Mary Beth; Shan Jianqin; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah A; Wierda William; Ferrajoli Allessandra; Jeha Sima; Kantarjian Hagop M
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Blood 2003;101(10):3794-800.
2003: Faderl Stefan; Thomas Deborah A; O'Brien Susan; Garcia-Manero Guillermo; Kantarjian Hagop M; Giles Francis J; Koller Charles; Ferrajoli Alessandra; Verstovsek Srdan; Pro Barbara; Andreeff Michael; Beran Miloslav; Cortes Jorge; Wierda William; Tran Ngoc; Keating Michael J
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
Blood 2003;101(9):3413-5.
2003: Ibrahim Sherif; Jilani Iman; O'Brien Susan; Rogers Anna; Manshouri Taghi; Giles Francis; Faderl Stefan; Thomas Deborah; Kantarjian Hagop; Keating Michael; Albitar Maher
Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia.
Cancer 2003;97(8):1914-9.
2003: Tsimberidou Apostolia M; Kantarjian Hagop M; Cortes Jorge; Thomas Deborah A; Faderl Stefan; Garcia-Manero Guillermo; Verstovsek Srdan; Ferrajoli Alessandra; Wierda William; Alvarado Yesid; O'Brien Susan M; Albitar Maher; Keating Michael J; Giles Francis J
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Cancer 2003;97(7):1711-20.
2003: Apostolidou Efrosyni; Estey Elihu; Cortes Jorge; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Tsimberidou Apostolia; Kantarjian Hagop; Giles Francis J
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.
Leukemia research 2003;27(4):301-4.
2003: Kantarjian Hagop M; Gandhi Varsha; Kozuch Peter; Faderl Stefan; Giles Francis; Cortes Jorge; O'Brien Susan; Ibrahim Nuhad; Khuri Fadlo; Du Min; Rios Mary Beth; Jeha Sima; McLaughlin Peter; Plunkett William; Keating Michael
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1167-73.
2003: Giles Francis J; Faderl Stefan; Thomas Deborah A; Cortes Jorge E; Garcia-Manero Guillermo; Douer Dan; Levine Alexandra M; Koller Charles A; Jeha Sima S; O'Brien Susan M; Estey Elihu H; Kantarjian Hagop M
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1050-6.
2003: Tsimberidou Apostolia; Estey Elihu; Cortes Jorge; Thomas Deborah; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Keating Michael; Albitar Maher; O'Brien Susan; Kantarjian Hagop; Giles Francis
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Cancer 2003;97(6):1481-7.
2003: Verstovsek Srdan; Kantarjian Hagop; Manshouri Taghi; Cortes Jorge; Faderl Stefan; Giles Francis J; Keating Michael; Albitar Maher
Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia.
Cancer 2003;97(5):1248-52.
2003: Cortes Jorge; Kantarjian Hagop; Albitar Maher; Thomas Deborah; Faderl Stefan; Koller Charles; Garcia-Manero Guillermo; Giles Francis; Andreeff Michael; O'Brien Susan; Keating Michael; Estey Elihu
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Cancer 2003;97(5):1234-41.
2003: Faderl Stefan; Lotan Reuben; Kantarjian Hagop M; Harris David; Van Quin; Estrov Zeev
N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).
Leukemia research 2003;27(3):259-66.
2003: Wierda William G; Johnson Marcella M; Do Kim-Anh; Manshouri Taghi; Dey Amanda; O'Brien Susan; Giles Francis J; Kantarjian Hagop; Thomas Deborah; Faderl Stefan; Lerner Susan; Keating Michael; Albitar Maher
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia.
British journal of haematology 2003;120(3):452-6.
2003: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge E; Shan Jianqin; Giles Francis J; Rios Mary Beth; Faderl Stefan H; Wierda William G; Ferrajoli Alessandra; Verstovsek Srdan; Keating Michael J; Freireich Emil J; Talpaz Moshe
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
Cancer 2003;97(4):1033-41.
2003: Kantarjian Hagop M; Talpaz Moshe; Cortes Jorge; O'Brien Susan; Faderl Stefan; Thomas Deborah; Giles Francis; Rios Mary Beth; Shan Jianqin; Arlinghaus Ralph
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):160-6.
2003: Alvarado Yesid; Tsimberidou Apostolia; Kantarjian Hagop; Cortes Jorge; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Estey Elihu; Giles Francis J
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
Cancer chemotherapy and pharmacology 2003;51(1):87-90.
2003: Alvarado Yesid; Cortes Jorge; Verstovsek Srdan; Thomas Deborah; Faderl Stephan; Estrov Zeev; Kantarjian Hagop; Giles Francis J
Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia.
Cancer chemotherapy and pharmacology 2003;51(1):81-6.
2003: Kantarjian Hagop M; Cortes Jorge E; O'Brien Susan; Giles Francis; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Jeha Sima; Rios Mary Beth; Letvak Laurie; Bochinski Kathy; Arlinghaus Ralph; Talpaz Moshe
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.
Blood 2003;101(1):97-100.
2003: Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Giles Francis; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Shan Jianqin; Rios Mary Beth; Cortes Jorge
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.
Blood 2003;101(2):473-5.
2002: Giles Francis J; Kantarjian Hagop M; Bekele B Nebiyou; Cortes Jorge E; Faderl Stephan; Thomas Deborah A; Manshouri Taghi; Rogers Anna; Keating Michael J; Talpaz Moshe; O'Brien Susan; Albitar Maher
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival.
British journal of haematology 2002;119(1):38-45.
2002: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge E; Giralt Sergio A; Rios Mary Beth; Shan Jianqin; Giles Francis J; Thomas Deborah A; Faderl Stefan; De Lima Marcos; Garcia-Manero Guillermo; Champlin Richard; Arlinghaus Ralph; Talpaz Moshe
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Blood 2002;100(5):1590-5.
2002: Garcia-Manero Guillermo; Faderl Stefan; Giles Francis; Thomas Deborah; Cortes Jorge; O'Brien Susan; Davis Jan; Kantarjian Hagop M; Estey Elihu
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Haematologica 2002;87(8):804-7.
2002: Ferrajoli Alessandra; Keating Michael J; Manshouri Taghi; Giles Francis J; Dey Amanda; Estrov Zeev; Koller Charles A; Kurzrock Razelle; Thomas Deborah A; Faderl Stefan; Lerner Susan; O'Brien Susan; Albitar Maher
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia.
Blood 2002;100(4):1215-9.
2002: Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Smith Terry L; Giles Francis J; Faderl Stefan; Thomas Deborah A; Garcia-Manero Guillermo; Issa Jean-Pierre J; Andreeff Michael; Kornblau Steven M; Koller Charles; Beran Milosav; Keating Michael; Rios Mary Beth; Shan Jenny; Resta Debra; Capdeville Renaud; Hayes Kimberly; Albitar Maher; Freireich Emil J; Cortes Jorge E
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2177-87.
2002: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge E; Smith Terry L; Rios Mary Beth; Shan Jianqin; Yang Ying; Giles Francis J; Thomas Deborah A; Faderl Stefan; Garcia-Manero Guillermo; Jeha Sima; Wierda William; Issa Jean-Pierre J; Kornblau Steven M; Keating Michael; Resta Debra; Capdeville Renaud; Talpaz Moshe
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2167-76.
2002: Giles Francis J; Cortes Jorge E; Thomas Deborah A; Garcia-Manero Guillermo; Faderl Stephan; Jeha Sima; De Jager Robert L; Kantarjian Hagop M
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2134-41.
2002: Ravandi Farhad; Cortes Jorge; Estrov Zeev; Thomas Deborah; Giles Francis J; Huh Yang O; Pierce Sherry; O'Brien Susan; Faderl Stefan; Kantarjian Hagop M
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.
Leukemia research 2002;26(7):643-9.
2002: Faderl Stefan; Garcia-Manero Guillermo; Thomas Deborah A; Kantarjian Hagop M
Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives.
Reviews in clinical and experimental hematology 2002;6(2):142-60; discussion 200-2.
2002: Faderl Stefan; Thall Peter F; Kantarjian Hagop M; Estrov Zeev
Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission.
British journal of haematology 2002;117(4):869-74.
2002: Faderl S; Keating M J; Do K-A; Liang S-Y; Kantarjian H M; O'Brien S; Garcia-Manero G; Manshouri T; Albitar M
Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(6):1045-52.
2002: Estey Elihu H; Giles Francis J; Beran Miloslav; O'Brien Susan; Pierce Sherry A; Faderl Stefan H; Cortes Jorge E; Kantarjian Hagop M
Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia.
Blood 2002;99(11):4222-4.
2002: Kantarjian Hagop M; Cortes Jorge; O'Brien Susan; Giles Francis J; Albitar Maher; Rios Mary Beth; Shan Jianqin; Faderl Stefan; Garcia-Manero Guillermo; Thomas Deborah A; Resta Debra; Talpaz Moshe
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Blood 2002;99(10):3547-53.
2002: Tsimberidou Apostolia M; O'Brien Susan M; Cortes Jorge E; Faderl Stefan; Andreeff Michael; Kantarjian Hagop M; Keating Michael J; Giles Francis J
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.
Leukemia & lymphoma 2002;43(4):767-72.
2002: O'Brien Susan; Talpaz Moshe; Cortes Jorge; Shan Jianqin; Giles Francis J; Faderl Stefan; Thomas Deborah; Garcia-Manero Guillermo; Mallard Susie; Beth Mary; Koller Charles; Kornblau Steve; Andreeff Michael; Murgo Anthony; Keating Michael; Kantarjian Hagop M
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
Cancer 2002;94(7):2024-32.
2002: Verstovsek Srdan; Kantarjian Hagop; Manshouri Taghi; O'Brien Susan; Faderl Stefan; Talpaz Moshe; Cortes Jorge; Albitar Maher
Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia.
Cancer 2002;94(5):1517-21.
2002: Cortes Jorge; Thomas Deborah; Rios Adan; Koller Charles; O'Brien Susan; Jeha Sima; Faderl Stefan; Kantarjian Hagop
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
Cancer 2002;94(5):1492-9.
2002: Surapaneni Usha R; Cortes Jorge E; Thomas Deborah; O'Brien Susan; Giles Francis J; Koller Charles; Faderl Stefan; Kantarjian Hagop
Central nervous system relapse in adults with acute lymphoblastic leukemia.
Cancer 2002;94(3):773-9.
2002: Faderl Stefan; Estrov Zeev
Shift of immunoglobulin phenotypes in B-cell precursor cell lines.
Leukemia research 2002;26(1):11-2.
2002: Faderl Stefan; Gandhi Varsha; Kantarjian Hagop; Plunkett William
New nucleoside analogues in clinical development.
Cancer chemotherapy and biological response modifiers 2002;20():37-58.
2001: Faderl S; Estrov Z; Kantarjian H M; Harris D; Van Q; Fokt I; Przewloka T; Godlewski C; Woynarowski J M; Priebe W
WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity.
Anticancer research 2001;21(6A):3777-84.
2001: Beran M; Shen Y; Kantarjian H; O'Brien S; Koller C A; Giles F J; Cortes J; Thomas D A; Faderl S; Despa S; Estey E H
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.
Cancer 2001;92(8):1999-2015.
2001: Talpaz M; O'Brien S; Rose E; Gupta S; Shan J; Cortes J; Giles F J; Faderl S; Kantarjian H M
Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.
Blood 2001;98(6):1708-13.
2001: Dabaja B S; O'Brien S M; Kantarjian H M; Cortes J E; Thomas D A; Albitar M; Schlette E S; Faderl S; Sarris A; Keating M J; Giles F J
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome.
Leukemia & lymphoma 2001;42(3):329-37.
2001: Ravandi F; Kantarjian H M; Talpaz M; O'Brien S; Faderl S; Giles F J; Thomas D; Cortes J; Andreeff M; Estrov Z; Rios M B; Albitar M
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.
Cancer 2001;91(11):1964-72.
2001: Faderl S; Estrov Z
The clinical significance of caspase regulation in acute leukemia.
Leukemia & lymphoma 2001;40(5-6):471-81.
2001: Faderl S; Gidel C; Kantarjian H M; Manshouri T; Keating M; Albitar M
Loss of heterozygosity on chromosome 5 in adults with acute lymphoblastic leukemia.
Leukemia research 2001;25(1):39-43.
2000: Faderl S; Albitar M
Insights into the biologic and molecular abnormalities in adult acute lymphocytic leukemia.
Hematology/oncology clinics of North America 2000;14(6):1267-88.
2000: Faderl S; Kantarjian H M; Talpaz M; Estrov Z
Clinical significance of minimal residual disease in leukemia.
International journal of oncology 2000;17(6):1277-87.
2000: Faderl S; Kantarjian H M; Estey E; Manshouri T; Chan C Y; Rahman Elsaied A; Kornblau S M; Cortes J; Thomas D A; Pierce S; Keating M J; Estrov Z; Albitar M
The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia.
Cancer 2000;89(9):1976-82.
2000: Kozuch P; Talpaz M; Faderl S; O'Brien S; Freireich E J; Kantarjian H
Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha: a synergistic correlation?
Cancer 2000;89(7):1482-9.
2000: Faderl S; Kantarjian H M; Thomas D A; Cortes J; Giles F; Pierce S; Albitar M; Estrov Z
Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Leukemia & lymphoma 2000;36(3-4):263-73.
1999: Faderl S; Thall P F; Kantarjian H M; Talpaz M; Harris D; Van Q; Beran M; Kornblau S M; Pierce S; Estrov Z
Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4041-7.
1999: Faderl S; Kurzrock R; Estrov Z
Minimal residual disease in hematologic disorders.
Archives of pathology & laboratory medicine 1999;123(11):1030-4.
1999: Faderl S; Estrov Z; Kantarjian H M; Thomas D; Cortes J; Manshouri T; Chan C C; Hays K J; Pierce S; Albitar M
The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia.
Cytokines, cellular & molecular therapy 1999;5(3):159-63.
1999: Thomas D A; Cortes J; O'Brien S; Pierce S; Faderl S; Albitar M; Hagemeister F B; Cabanillas F F; Murphy S; Keating M J; Kantarjian H
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2461-70.
1999: Faderl S; Talpaz M; Estrov Z; Kantarjian H M
Chronic myelogenous leukemia: biology and therapy.
Annals of internal medicine 1999;131(3):207-19.
1999: Faderl S; Kantarjian H M; Manshouri T; Chan C Y; Pierce S; Hays K J; Cortes J; Thomas D; Estrov Z; Albitar M
The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1855-61.
1999: Faderl S; Talpaz M; Estrov Z; O'Brien S; Kurzrock R; Kantarjian H M
The biology of chronic myeloid leukemia.
The New England journal of medicine 1999;341(3):164-72.
1999: Dabaja B S; Faderl S; Thomas D; Cortes J; O'Brien S; Nasr F; Pierce S; Hayes K; Glassman A; Keating M; Kantarjian H M
Deletions and losses in chromosomes 5 or 7 in adult acute lymphocytic leukemia: incidence, associations and implications.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(6):869-72.
1999: Faderl S; Talpaz M; Kantarjian H M; Estrov Z
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
Blood 1999;93(9):2755-9.
1999: Faderl S; Kantarjian H M; Talpaz M
Chronic myelogenous leukemia: update on biology and treatment.
Oncology (Williston Park, N.Y.) 1999;13(2):169-80; discussion 181, 184.
1998: Faderl S; Estrov Z
The clinical significance of detection of residual disease in childhood ALL.
Critical reviews in oncology/hematology 1998;28(1):31-55.
1998: Faderl S; Estrov Z
Residual disease in acute lymphoblastic leukemia of childhood: methods of detection and clinical relevance.
Cytokines, cellular & molecular therapy 1998;4(2):73-85.
1998: Faderl S; Kantarjian H M; Talpaz M; Estrov Z
Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia.
Blood 1998;91(11):3995-4019.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Stefan Faderl

Research Profile (preview)

Concepts & Ideas

Chemicals & Drugs

Disorders

Procedures

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Stefan Faderl (preview)

All Publications